| Previous Close | 0.19 |
| Open | 0.19 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 0.19 - 0.22 |
| 52 Week Range | 0.10 - 0.64 |
| Volume | 176,498 |
| Avg. Volume | 160,917 |
| Market Cap | 30.929M |
| Beta | -3.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
SUWANEE, GA, Sept. 06, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave, Inc. will exhibit the dermaPACE® device at the 35th Annual National Tribal Health Conference at the Oklahoma City Cox Convention Center in Oklahoma City, OK, September 17 - 20, 2018. The National Tribal Health Conference is the largest American Indian and Alaska Native specific gathering focused on health every year.
Q2 Results, Operational Update: International Expansion Continues With 2 New JVs Signed in Q2…. Revenue continues to gain momentum, reflecting initial contribution from the recent U.S. launch and, to a greater degree, SNWV’s ever-expanding international footprint. Q2 revenue of $453k, which is the second-highest quarterly revenue in company history, was up more than 300% from the prior year and 32% from Q1 ’18.
PHOENIX, Aug. 21, 2018 (GLOBE NEWSWIRE) -- (SNWV) -- SANUWAVE Health, Inc.’s Chairman and CEO, Kevin Richardson, Returns to Uptick Newswire’s “Stock Day” Podcast to report on a 300% increase in revenue. Richardson responded that the Company had its best 2nd Quarter ever. The sales in the 2nd Quarter were driven by international deals that really came to light because of the FDA approval.
SUWANEE, Ga., Aug. 14, 2018-- SANUWAVE Health, Inc. reported financial results for the three months ended June 30, 2018 with the SEC on Tuesday, August 14, 2018 and will provide a business update on a ...
SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the second quarter ended June 30, 2018, on August 13, 2018. The Company will also host a conference call on Tuesday, August 14, 2018, beginning at 10AM Eastern Time to discuss the second quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.
SANUWAVE Health, Inc. (SNWV) is pleased to announce a partnership with HyperMed in Memphis, TN to sponsor a continuing clinical investigation on Diabetic Foot Ulcers (DFUs). This investigational work is expected to begin in August 2018. An initial case series will be conducted at two sites, the primary site being the Vascular and Wound Care Center at University Hospital, Rutgers NJMS in Newark, NJ with Dr. Oscar Alvarez as the Principal Investigator, and the second site at Olive View-UCLA Medical Center with Dr. Aksone Nouvong leading the efforts. As a result of Dr. Alvarez’s leadership and case work, he will be able to provide SANWUAVE with valuable, measurable data to continue to expand our understanding of the dermaPACE® System’s mechanism of action. Dr. Nouvong has already performed and published extensive research using the HyperView spectral imaging device. These two renowned investigators and practitioners in wound care, with their combined expertise, will expand the already extensive clinical data associated with dermaPACE®. Both researchers participated in previous dermaPACE® DFU trials.
SUWANEE, GA., June 28, 2018-- SANUWAVE Health, Inc. SANUWAVE is pleased to announce that since receiving clearance from the FDA in late December 2017, its presence has been increasing in the medical device ...
SANUWAVE Health, Inc. (SNWV) is pleased to announce a signed Joint Venture (JV) agreement with FKS, a JohnFK Medical company in Southeast Asia. The first of two exclusivity fees have been received with a second scheduled for the third quarter 2018. The Agreement will cover Taiwan, Singapore, Malaysia, Brunei, Cambodia, Myanmar, Laos, Thailand, Philippines, Indonesia and Vietnam. The JV is expected to place at least 40 devices during 2018 and over 200 in the first three years, with the first shipments going out in the third quarter of 2018. The agreement is similar to other international JV’s entered into by SANUWAVE in that, the profits are shared equally among the partners, a management committee exists to ensure success of the JV, and exclusivity fees are involved to ensure mutual success. The agreement also stipulates that one of SANUWAVE Health’s long-time science advisors, Dr. Wang, will be a consultant to the JV.
The Company, which was a start-up research and development company is now moving into the commercialization phase. SANUWAVE has continued to make strides on achieving its goal to treat every wound everywhere. Most recently the Company confirmed a deal that will increase its international footprint into southeast Asia.
SUWANEE, GA, June 26, 2018-- SANUWAVE Health, Inc. is excited to announce the execution of a binding term sheet for a Joint Venture with Tarbaca Lightning, the distribution company of Latin America Pharma ...
Q1 ’18 marked a milestone for SNWV - or more accurately, marked three milestones. The $344k of revenue is the highest Q1 revenue in company history and it included U.S. dermaPACE revenue – which is another first. U.S. dermaPACE revenue relates to the first shipments to Premier Shockwave.
With the U.S. strategy firming up, including initial distribution through Premier Shockwave (targeting VA and Indian Health) and initiation of various clinical (marketing-focused) clinical studies, SNWV is wasting no time in capitalizing on the domestic opportunity. Management expects revenue contribution from the U.S. as early as Q1 – and (mostly) depending on initial rates of VA-related adoption and utilization as well as (likely more incremental) OVA (i.e.